Connect Ovar Coffee

In Part II of All Things Ovarian and Gynecologic Cancers, we explore the rapidly evolving treatment landscape in ovarian as well as a few other gynecologic cancers with world renowned gynecologic oncologist Dr. Rob Coleman, in observance of Gynecologic Cancers Awareness Month.

We are honored to welcome Dr. Robert Coleman, a world-renowned gynecologic oncologist and researcher, for Part 1 of a two-part conversation exploring where we are today, and where we go next as the science of ovarian and gynecologic cancers continues to progress.

We sit down on this episode to Connect Ovar Coffee with with Global Expert Dr. Angeles Secord, the Lead Investigator of the RINA-S trial, the former President of the Society of Gynecologic Oncology and Professor, Gynecologic Oncology, at Duke University Cancer Center, to talk about: 1. Biomarkers - established, emerging, and in the pipeline 2. Clinical Trials, focusing on RINA - S3. ADCs 4. Combination Therapies 5. + Much More

Connect Ovar Coffee: Dr. Alexander OlawaiyeThis episode features Dr. Alexander Olawaiye, discussing major advances in ovarian cancer treatment, including the ROSELLA clinical trial.  Key Highlights: 1. Ovarian Cancer Challenges: - No reliable early screening methods - Majority diagnosed at advanced stages (Stage III/IV) - Early detection remains a critical unmet need 2. ROSELLA Trial Breakthrough: - Focus on platinum-resistant ovarian cancer - Combines relacorilant (a glucocorticoid receptor antagonist) with nab-paclitaxel - Demonstrated improved progression-free survival and overall survival - No biomarker requirement, making it accessible to more patients 3. Mechanism of Action: - Relacorilant blocks cortisol signaling that promotes chemotherapy resistance - Enhances effectiveness of chemotherapy 4. Safety & Tolerability: - No new major toxicities identified - Side effects consistent with standard chemotherapy 5. Clinical Trial Importance: - Patients in trials often experience better outcomes - Participation helps advance future treatments 6. Health Equity & Access: - Disparities exist in access to care and clinical trials - Need to improve awareness, access, and inclusion 7. Future Outlook: - Rapid growth in new treatments over past decade - Emerging therapies include antibody-drug conjugates - Continued innovation offers hope for patients  Closing Message:Stay informed, consider clinical trials, and remain hopeful as new treatments continue to emerge. 

1. Future of Gynecologic Oncology and Clinical Trials 2. ADCs (antibody drug conjugates) - what we should know 3. Immunity and Immunotherapy 4. CAR-T Cell Therapy 5. Vaccines + MORE! We discuss on this episode of Connect Ovar Coffee with the Chair of Gynecologic Oncology at Moffitt Cancer Center, Dr. Robert Wenham. Learn, Share and Be Empowered 💪.Let's #ConnectOvarCoffee

"You have to feel that you are in the right setting with the right physician who is taking care of YOU personally" Connect Ovar Coffee ☕️ 2026 is off to a blazing start with an outstanding chat with our Advisory Board Member and Globally renowned Expert Surgeon, Dr. Pedro Ramirez, Chair of OB-GYN at the Houston Methodist. 52 minutes of knowledge, information, compassion and candid guidance - share with anyone who may benefit. Subscribe. Listen. Learn. Share. Be Empowered! Let's #ConnectOvarCoffee! 

In this episode of Connect Ovar Coffee, Dr. Premal Thaker, Director of Gynecologic Oncology at Washington University School of Medicine in St. Louis joins us to talk about treatment transformations in ovarian and gynecologic cancers and what we should be hopeful for in 2026. All the latest science, right here for you. Let's #ConnectOvarCoffee!

In this episode, Physician Scientist Dr. Emil Lou, Professor, University of Minnesota School of Medicine discusses how to Break The Code on the biology of #ovariancancer cells as they relate to cell invasion, progression, tumor recurrence, and chemotherapy resistance. Listen to this fascinating discussion and share with others. This is how we Ovarcome! 

Join us as we Connect Ovar Coffee ☕️ with Dr. Brian Slomovitz to talk about the latest advances in gynecologic cancers.  A renowned specialist in clinical trial development, robotic surgery, and immunotherapy, Dr. Brian Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center of Florida. Be there. Be INFORMED. Be EMPOWERED! Let's Connect Ovar Coffee! 

Kicking off season 6 with a special episode dedicated to our Granulosa Cell Tumor (GCT) community . GCTs account for just 2–5% of all ovarian cancers, making them rare and in need of specialized care.Joining us on this episode is world-renowned expert Dr. Tyler Hillman, whose work is at the forefront of GCT treatment and research into its molecular origins. Join us for this insightful episode as we take a deep dive into the science, advances and strategies in managing GCT.Learn. Share. Be Empowered. Let’s #ConnectOvarCoffee!